JP2004502642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502642A5 JP2004502642A5 JP2001558420A JP2001558420A JP2004502642A5 JP 2004502642 A5 JP2004502642 A5 JP 2004502642A5 JP 2001558420 A JP2001558420 A JP 2001558420A JP 2001558420 A JP2001558420 A JP 2001558420A JP 2004502642 A5 JP2004502642 A5 JP 2004502642A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- methyl
- morpholinyl
- alkyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 description 62
- 239000001257 hydrogen Substances 0.000 description 62
- 125000000217 alkyl group Chemical group 0.000 description 60
- 150000001875 compounds Chemical class 0.000 description 53
- 150000002431 hydrogen Chemical class 0.000 description 51
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 46
- 125000003118 aryl group Chemical group 0.000 description 35
- 125000000753 cycloalkyl group Chemical group 0.000 description 32
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 29
- -1 alkylamide Chemical group 0.000 description 28
- 125000003545 alkoxy group Chemical group 0.000 description 27
- 229910052757 nitrogen Inorganic materials 0.000 description 26
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 25
- 125000000547 substituted alkyl group Chemical group 0.000 description 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 21
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 17
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 125000005017 substituted alkenyl group Chemical group 0.000 description 15
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 13
- 125000004103 aminoalkyl group Chemical group 0.000 description 12
- 125000004093 cyano group Chemical group *C#N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 125000004426 substituted alkynyl group Chemical group 0.000 description 11
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical class C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 208000023504 respiratory system disease Diseases 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000003520 cannabinoid receptor affecting agent Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 0 CC(*)(C1N2*)[C@]1c([n](**)c1c3C=CC(*)(*)C=C1*)c3C2=O Chemical compound CC(*)(C1N2*)[C@]1c([n](**)c1c3C=CC(*)(*)C=C1*)c3C2=O 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 150000001602 bicycloalkyls Chemical group 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 230000008518 non respiratory effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- CTKINSOISVBQLD-GSVOUGTGSA-N (R)-Glycidol Chemical compound OC[C@@H]1CO1 CTKINSOISVBQLD-GSVOUGTGSA-N 0.000 description 1
- RKZCDADRRFKROG-KMGMCLHJSA-N 1-(2-cyclohexylethyl)-7-methoxy-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CCC1CCCCC1 RKZCDADRRFKROG-KMGMCLHJSA-N 0.000 description 1
- NGBQGZULVBXWKI-MNIAQESNSA-N 1-(2-ethoxyethyl)-7-methoxy-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C12=CC=CC(OC)=C2N(CCOCC)C(C)=C1C(=O)N[C@H]1[C@@](C2)(C)CCC2C1(C)C NGBQGZULVBXWKI-MNIAQESNSA-N 0.000 description 1
- UMSJZSKEUCVDDU-UCPOHXDKSA-N 1-(2-morpholin-4-ylethyl)-5-nitro-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrazole-3-carboxamide Chemical compound N([C@@H]1C(C)(C)C2CC[C@]1(C2)C)C(=O)C(=N1)C=C([N+]([O-])=O)N1CCN1CCOCC1 UMSJZSKEUCVDDU-UCPOHXDKSA-N 0.000 description 1
- ZSBNYNLNQAALQY-XHYACHTCSA-N 1-(2-morpholin-4-ylethyl)-5-pentoxy-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrazole-3-carboxamide Chemical compound CCCCCOC1=CC(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=NN1CCN1CCOCC1 ZSBNYNLNQAALQY-XHYACHTCSA-N 0.000 description 1
- GOTMKWHLCZVWNF-MNIAQESNSA-N 1-[2-(dimethylamino)ethyl]-7-methoxy-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound COC1=CC=CC2=C1N(CCN(C)C)C(C)=C2C(=O)N[C@H]1[C@@](C2)(C)CCC2C1(C)C GOTMKWHLCZVWNF-MNIAQESNSA-N 0.000 description 1
- SAPSVILUXSCISL-KMGMCLHJSA-N 1-[2-[di(propan-2-yl)amino]ethyl]-7-methoxy-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound COC1=CC=CC2=C1N(CCN(C(C)C)C(C)C)C(C)=C2C(=O)N[C@@H]1C(C)(C)C2CC[C@@]1(C)C2 SAPSVILUXSCISL-KMGMCLHJSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- YECUDGCOHUBKEM-QGZVFWFLSA-N 2,5-dimethyl-1-(2-morpholin-4-ylethyl)-n-[(2r)-1-phenylpropan-2-yl]pyrrole-3-carboxamide Chemical compound C([C@@H](C)NC(=O)C1=C(N(CCN2CCOCC2)C(C)=C1)C)C1=CC=CC=C1 YECUDGCOHUBKEM-QGZVFWFLSA-N 0.000 description 1
- VARGLVSWMATKND-UCPOHXDKSA-N 2-(2-morpholin-4-ylethyl)-5-nitro-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrazole-3-carboxamide Chemical compound N([C@@H]1C(C)(C)C2CC[C@]1(C2)C)C(=O)C1=CC([N+]([O-])=O)=NN1CCN1CCOCC1 VARGLVSWMATKND-UCPOHXDKSA-N 0.000 description 1
- NAFSGIMUDROETJ-UHFFFAOYSA-N 2-[(2,6-dimethylphenyl)methyl]-6-methoxy-5-(2-morpholin-4-ylethyl)pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N(CC=3C(=CC=CC=3C)C)C=CC=22)=C1N2CCN1CCOCC1 NAFSGIMUDROETJ-UHFFFAOYSA-N 0.000 description 1
- UKWKFSKFWUTFRX-UHFFFAOYSA-N 2-[(2-fluorophenyl)methyl]-6-methoxy-5-(2-morpholin-4-ylethyl)pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N(CC=3C(=CC=CC=3)F)C=CC=22)=C1N2CCN1CCOCC1 UKWKFSKFWUTFRX-UHFFFAOYSA-N 0.000 description 1
- UAAIPGIFCADKPE-UHFFFAOYSA-N 2-cyclopentyl-6-methoxy-5-(2-morpholin-4-ylethyl)pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N(C3CCCC3)C=CC=22)=C1N2CCN1CCOCC1 UAAIPGIFCADKPE-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- JIXREYOBFPHPQG-UWJIBMLQSA-N 2-methyl-1-(2-morpholin-4-ylethyl)-4,5-diphenyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrrole-3-carboxamide Chemical compound C1COCCN1CCN1C(C)=C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JIXREYOBFPHPQG-UWJIBMLQSA-N 0.000 description 1
- JWPGFZBOKXSSAE-LFXFHBMYSA-N 2-methyl-1-(2-morpholin-4-ylethyl)-5-phenyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrrole-3-carboxamide Chemical compound C1COCCN1CCN1C(C)=C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)C=C1C1=CC=CC=C1 JWPGFZBOKXSSAE-LFXFHBMYSA-N 0.000 description 1
- STTXUMSIHQWORP-UHFFFAOYSA-N 2-methyl-1-(2-morpholin-4-ylethyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)pyrrole-3-carboxamide Chemical compound CC1=C(C(=O)NC2C(C3CCC2(C)C3)(C)C)C=CN1CCN1CCOCC1 STTXUMSIHQWORP-UHFFFAOYSA-N 0.000 description 1
- AMFCVKOCHWUBAG-NRFANRHFSA-N 2-methyl-n-[(1s)-1-(3-methyl-1,2,4-oxadiazol-5-yl)-2-phenylethyl]-1-(2-morpholin-4-ylethyl)pyrrole-3-carboxamide Chemical compound CC1=NOC([C@H](CC=2C=CC=CC=2)NC(=O)C2=C(N(CCN3CCOCC3)C=C2)C)=N1 AMFCVKOCHWUBAG-NRFANRHFSA-N 0.000 description 1
- WVKPYYLOFMTDHB-UHFFFAOYSA-N 2-norbornyl radical Chemical group C1CC2[CH]CC1C2 WVKPYYLOFMTDHB-UHFFFAOYSA-N 0.000 description 1
- OLWWQYROAWRRMR-UHFFFAOYSA-N 3,4-dihydro-2h-quinolin-1-yl-[5-fluoro-7-methoxy-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone Chemical compound C1=2C(OC)=CC(F)=CC=2C(C(=O)N2C3=CC=CC=C3CCC2)=C(C)N1CCN1CCOCC1 OLWWQYROAWRRMR-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- BMYHCXBZNSSQFT-OGGJSMKJSA-N 5,7-dimethoxy-2-methyl-1-(2-morpholin-4-ylethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound CC1=C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)C2=CC(OC)=CC(OC)=C2N1CCN1CCOCC1 BMYHCXBZNSSQFT-OGGJSMKJSA-N 0.000 description 1
- MXJVPIIMPVGSCK-DLOYZTDZSA-N 5-benzyl-6-methoxy-2-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N([C@H]3[C@@]4(C)CCC(C4)C3(C)C)C=CC=22)=C1N2CC1=CC=CC=C1 MXJVPIIMPVGSCK-DLOYZTDZSA-N 0.000 description 1
- BPCWSLRVZAOONI-XMWUBULVSA-N 5-butyl-6-methoxy-2-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrido[4,3-b]indol-1-one Chemical compound C12=CC=CC(OC)=C2N(CCCC)C2=C1C(=O)N([C@H]1[C@@]3(C)CCC(C3)C1(C)C)C=C2 BPCWSLRVZAOONI-XMWUBULVSA-N 0.000 description 1
- FINTYTPBRFYBCW-QPBYVCLMSA-N 5-fluoro-7-methoxy-2-methyl-1-(2-morpholin-4-ylethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC(F)=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CCN1CCOCC1 FINTYTPBRFYBCW-QPBYVCLMSA-N 0.000 description 1
- YJBCXXBDTPUCPP-OGGJSMKJSA-N 5-fluoro-7-methoxy-2-methyl-1-(3-morpholin-4-ylpropyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC(F)=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CCCN1CCOCC1 YJBCXXBDTPUCPP-OGGJSMKJSA-N 0.000 description 1
- LIJWNPZQIZRZFJ-UHFFFAOYSA-N 5-fluoro-7-methoxy-n-(2-methoxyphenyl)-2-methyl-1-(2-morpholin-4-ylethyl)indole-3-carboxamide Chemical compound COC1=CC=CC=C1NC(=O)C(C1=CC(F)=CC(OC)=C11)=C(C)N1CCN1CCOCC1 LIJWNPZQIZRZFJ-UHFFFAOYSA-N 0.000 description 1
- XXZCLKCFTHJCQG-LIRQYPNKSA-N 5-methoxy-1-(2-morpholin-4-ylethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrazole-3-carboxamide Chemical compound COC1=CC(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=NN1CCN1CCOCC1 XXZCLKCFTHJCQG-LIRQYPNKSA-N 0.000 description 1
- DHWXPOMVUUYBGK-UHFFFAOYSA-N 6-methoxy-2-(2-methoxyethyl)-5-(2-morpholin-4-ylethyl)pyrido[4,3-b]indol-1-one Chemical compound C12=C(OC)C=CC=C2C=2C(=O)N(CCOC)C=CC=2N1CCN1CCOCC1 DHWXPOMVUUYBGK-UHFFFAOYSA-N 0.000 description 1
- XIOBJOPZJWKCIV-UHFFFAOYSA-N 6-methoxy-2-(2-methoxyphenyl)-5-(2-morpholin-4-ylethyl)pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC=C1N1C(=O)C(C2=CC=CC(OC)=C2N2CCN3CCOCC3)=C2C=C1 XIOBJOPZJWKCIV-UHFFFAOYSA-N 0.000 description 1
- JTHVKCNGXTTXIF-HXUWFJFHSA-N 6-methoxy-5-(2-morpholin-4-ylethyl)-2-[(2r)-1-phenylpropan-2-yl]pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N([C@H](C)CC=3C=CC=CC=3)C=CC=22)=C1N2CCN1CCOCC1 JTHVKCNGXTTXIF-HXUWFJFHSA-N 0.000 description 1
- QYOXVDHZVYJTMY-IMIJRDQBSA-N 6-methoxy-5-(2-morpholin-4-ylethyl)-2-[(3r,4r)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N([C@H]3C(C4CC[C@]3(C)C4)(C)C)C=CC=22)=C1N2CCN1CCOCC1 QYOXVDHZVYJTMY-IMIJRDQBSA-N 0.000 description 1
- QYOXVDHZVYJTMY-OGGJSMKJSA-N 6-methoxy-5-(2-morpholin-4-ylethyl)-2-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]pyrido[4,3-b]indol-1-one Chemical compound COC1=CC=CC(C=2C(=O)N([C@@H]3C(C4CC[C@@]3(C)C4)(C)C)C=CC=22)=C1N2CCN1CCOCC1 QYOXVDHZVYJTMY-OGGJSMKJSA-N 0.000 description 1
- UFNLQUUMXCSEQA-UHFFFAOYSA-N 6-methoxy-5-(2-morpholin-4-ylethyl)-2-propylpyrido[4,3-b]indol-1-one Chemical compound C12=C(OC)C=CC=C2C=2C(=O)N(CCC)C=CC=2N1CCN1CCOCC1 UFNLQUUMXCSEQA-UHFFFAOYSA-N 0.000 description 1
- RGLUCTFRNHDAOB-KVVHPSQQSA-N 7-methoxy-1-(2-methoxyethyl)-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C12=CC=CC(OC)=C2N(CCOC)C(C)=C1C(=O)N[C@H]1[C@@](C2)(C)CCC2C1(C)C RGLUCTFRNHDAOB-KVVHPSQQSA-N 0.000 description 1
- CPTXZVAIZCMESQ-UHFFFAOYSA-N 7-methoxy-1-(2-morpholin-4-ylethyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC2C(C3CCC2(C)C3)(C)C)=NN1CCN1CCOCC1 CPTXZVAIZCMESQ-UHFFFAOYSA-N 0.000 description 1
- VQGDMQICNRCQEH-UHFFFAOYSA-N 7-methoxy-1-(2-morpholin-4-ylethyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC2C(C3CCC2(C)C3)(C)C)=CN1CCN1CCOCC1 VQGDMQICNRCQEH-UHFFFAOYSA-N 0.000 description 1
- JSRQMGXAMVWHLE-UHFFFAOYSA-N 7-methoxy-1-(2-morpholin-4-ylethyl)-n-(2,2,6,6-tetramethylcyclohexyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC2C(CCCC2(C)C)(C)C)=NN1CCN1CCOCC1 JSRQMGXAMVWHLE-UHFFFAOYSA-N 0.000 description 1
- QRPFZKVPDUOZAU-UHFFFAOYSA-N 7-methoxy-1-(2-morpholin-4-ylethyl)-n-naphthalen-1-ylindazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC=2C3=CC=CC=C3C=CC=2)=NN1CCN1CCOCC1 QRPFZKVPDUOZAU-UHFFFAOYSA-N 0.000 description 1
- IEPNKLPPFVSJSN-DLOYZTDZSA-N 7-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1C2=C(OC)C=CC=C2C(C(=O)N[C@H]2[C@@]3(C)CCC(C3)C2(C)C)=C1C IEPNKLPPFVSJSN-DLOYZTDZSA-N 0.000 description 1
- XWGGGOMMJKYRJR-UHFFFAOYSA-N 7-methoxy-2-methyl-1-(2-morpholin-4-ylethyl)-n-(2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl)indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC2C(C3CCC2(C)C3)(C)C)=C(C)N1CCN1CCOCC1 XWGGGOMMJKYRJR-UHFFFAOYSA-N 0.000 description 1
- SWXSXJGOHIPCQP-DLOYZTDZSA-N 7-methoxy-2-methyl-1-(2-phenoxyethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@H]2[C@@]3(C)CCC(C3)C2(C)C)=C(C)N1CCOC1=CC=CC=C1 SWXSXJGOHIPCQP-DLOYZTDZSA-N 0.000 description 1
- SQTXGPFIQPMERT-DXIPVMJCSA-N 7-methoxy-2-methyl-1-(2-piperidin-4-ylethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CCC1CCNCC1 SQTXGPFIQPMERT-DXIPVMJCSA-N 0.000 description 1
- JNOBXWYKDSWKHL-ZGOHAYIYSA-N 7-methoxy-2-methyl-1-(2-pyrrolidin-1-ylethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@H]2[C@@]3(C)CCC(C3)C2(C)C)=C(C)N1CCN1CCCC1 JNOBXWYKDSWKHL-ZGOHAYIYSA-N 0.000 description 1
- XWRHWCKKYSXXDL-ZGOHAYIYSA-N 7-methoxy-2-methyl-1-(pyridin-3-ylmethyl)-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CC1=CC=CN=C1 XWRHWCKKYSXXDL-ZGOHAYIYSA-N 0.000 description 1
- SULYTHAJECIDRM-NTEAZJJZSA-N 7-methoxy-2-methyl-1-[2-(1-methylpyrrolidin-2-yl)ethyl]-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@H]2[C@@]3(C)CCC(C3)C2(C)C)=C(C)N1CCC1CCCN1C SULYTHAJECIDRM-NTEAZJJZSA-N 0.000 description 1
- DJHGDVDDQPYURF-KMGMCLHJSA-N 7-methoxy-2-methyl-1-[3-(4-methylpiperazin-1-yl)propyl]-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H]2C(C3CC[C@@]2(C)C3)(C)C)=C(C)N1CCCN1CCN(C)CC1 DJHGDVDDQPYURF-KMGMCLHJSA-N 0.000 description 1
- RPGZRVZCBGRDRB-QQBUZJHSSA-N 7-methoxy-2-methyl-1-pentyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide Chemical compound C12=CC=CC(OC)=C2N(CCCCC)C(C)=C1C(=O)N[C@H]1[C@@](C2)(C)CCC2C1(C)C RPGZRVZCBGRDRB-QQBUZJHSSA-N 0.000 description 1
- GFWZOUZKTAJZMA-QYWJTTNJSA-N 7-methoxy-2-methyl-n-[(3s,4s)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]-1h-indole-3-carboxamide Chemical compound COC1=CC=CC2=C1NC(C)=C2C(=O)N[C@@H]1C(C)(C)C2CC[C@@]1(C)C2 GFWZOUZKTAJZMA-QYWJTTNJSA-N 0.000 description 1
- XZPAOPCTRNKGEW-UHFFFAOYSA-N 7-methoxy-n-(2-methoxy-5-methylphenyl)-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound COC1=CC=C(C)C=C1NC(=O)C(C1=CC=CC(OC)=C11)=NN1CCN1CCOCC1 XZPAOPCTRNKGEW-UHFFFAOYSA-N 0.000 description 1
- OLUHPADYRYQIDW-UHFFFAOYSA-N 7-methoxy-n-(2-methoxyphenyl)-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound COC1=CC=CC=C1NC(=O)C(C1=CC=CC(OC)=C11)=NN1CCN1CCOCC1 OLUHPADYRYQIDW-UHFFFAOYSA-N 0.000 description 1
- ALYXSSFEDASHDJ-FQEVSTJZSA-N 7-methoxy-n-[(1s)-1-(2-methyltetrazol-5-yl)-2-phenylethyl]-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H](CC=2C=CC=CC=2)C2=NN(C)N=N2)=NN1CCN1CCOCC1 ALYXSSFEDASHDJ-FQEVSTJZSA-N 0.000 description 1
- OMRMTIYZBXTTOP-UHFFFAOYSA-N 7-methoxy-n-[(2-methoxyphenyl)methyl]-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound COC1=CC=CC=C1CNC(=O)C(C1=CC=CC(OC)=C11)=NN1CCN1CCOCC1 OMRMTIYZBXTTOP-UHFFFAOYSA-N 0.000 description 1
- YLPNKBNBWHXBFF-UHFFFAOYSA-N 7-methoxy-n-methyl-n-(3-methylphenyl)-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N(C)C=2C=C(C)C=CC=2)=NN1CCN1CCOCC1 YLPNKBNBWHXBFF-UHFFFAOYSA-N 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- XCVSUBXPCXFEKN-SFHVURJKSA-N [(2s)-2-(methoxymethyl)pyrrolidin-1-yl]-[1-(2-morpholin-4-ylethyl)-5-pentoxypyrazol-3-yl]methanone Chemical compound CCCCCOC1=CC(C(=O)N2[C@@H](CCC2)COC)=NN1CCN1CCOCC1 XCVSUBXPCXFEKN-SFHVURJKSA-N 0.000 description 1
- VFZWVZXGXPNSIY-LOACHALJSA-N [(2s)-2-(methoxymethyl)pyrrolidin-1-yl]-[7-(morpholin-4-ylmethyl)-6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound COC[C@@H]1CCCN1C(=O)C1=NN2C(CN3CCOCC3)CCOC2=C1 VFZWVZXGXPNSIY-LOACHALJSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- IGWVDMIHDOVSLO-UHFFFAOYSA-N n-(2-ethylphenyl)-5-fluoro-7-methoxy-2-methyl-1-(2-morpholin-4-ylethyl)indole-3-carboxamide Chemical compound CCC1=CC=CC=C1NC(=O)C(C1=CC(F)=CC(OC)=C11)=C(C)N1CCN1CCOCC1 IGWVDMIHDOVSLO-UHFFFAOYSA-N 0.000 description 1
- CIAWPBGHCLCHDG-UHFFFAOYSA-N n-(4-fluorophenyl)-7-methoxy-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)NC=2C=CC(F)=CC=2)=NN1CCN1CCOCC1 CIAWPBGHCLCHDG-UHFFFAOYSA-N 0.000 description 1
- OKWBNHVZFDQPFV-UHFFFAOYSA-N n-(5-chloro-2-methoxyphenyl)-7-methoxy-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound COC1=CC=C(Cl)C=C1NC(=O)C(C1=CC=CC(OC)=C11)=NN1CCN1CCOCC1 OKWBNHVZFDQPFV-UHFFFAOYSA-N 0.000 description 1
- VRLOEKGMYGEXSQ-CQSZACIVSA-N n-[(2r)-butan-2-yl]-5-fluoro-7-methoxy-2-methyl-1-(2-morpholin-4-ylethyl)indole-3-carboxamide Chemical compound C12=C(OC)C=C(F)C=C2C(C(=O)N[C@H](C)CC)=C(C)N1CCN1CCOCC1 VRLOEKGMYGEXSQ-CQSZACIVSA-N 0.000 description 1
- GHCVCXTUXXGJRL-IBGZPJMESA-N n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]-7-methoxy-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H](CC=2C=CC=CC=2)C(N)=O)=NN1CCN1CCOCC1 GHCVCXTUXXGJRL-IBGZPJMESA-N 0.000 description 1
- FRGGVSWJEBUPRL-NRFANRHFSA-N n-[(2s)-1-hydroxy-3-phenylpropan-2-yl]-2-methyl-1-(2-morpholin-4-ylethyl)indole-3-carboxamide Chemical compound C([C@@H](CO)NC(=O)C1=C(N(C2=CC=CC=C21)CCN1CCOCC1)C)C1=CC=CC=C1 FRGGVSWJEBUPRL-NRFANRHFSA-N 0.000 description 1
- RIZAADJUTMSLDP-OAQYLSRUSA-N n-[(3r)-1-benzylpyrrolidin-3-yl]-7-methoxy-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@H]2CN(CC=3C=CC=CC=3)CC2)=NN1CCN1CCOCC1 RIZAADJUTMSLDP-OAQYLSRUSA-N 0.000 description 1
- RIZAADJUTMSLDP-NRFANRHFSA-N n-[(3s)-1-benzylpyrrolidin-3-yl]-7-methoxy-1-(2-morpholin-4-ylethyl)indazole-3-carboxamide Chemical compound C1=2C(OC)=CC=CC=2C(C(=O)N[C@@H]2CN(CC=3C=CC=CC=3)CC2)=NN1CCN1CCOCC1 RIZAADJUTMSLDP-NRFANRHFSA-N 0.000 description 1
- 125000004971 nitroalkyl group Chemical group 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZUGVYAVSPOHDQS-UHFFFAOYSA-N pyrido[4,3-b]indol-1-one Chemical compound C1=CC=CC2=C3C(=O)N=CC=C3N=C21 ZUGVYAVSPOHDQS-UHFFFAOYSA-N 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18181800P | 2000-02-11 | 2000-02-11 | |
| PCT/US2001/004131 WO2001058869A2 (en) | 2000-02-11 | 2001-02-08 | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004502642A JP2004502642A (ja) | 2004-01-29 |
| JP2004502642A5 true JP2004502642A5 (enExample) | 2008-03-13 |
Family
ID=22665935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001558420A Pending JP2004502642A (ja) | 2000-02-11 | 2001-02-08 | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6653304B2 (enExample) |
| EP (1) | EP1254115A2 (enExample) |
| JP (1) | JP2004502642A (enExample) |
| AR (1) | AR027406A1 (enExample) |
| AU (1) | AU2001234958A1 (enExample) |
| CA (1) | CA2399791A1 (enExample) |
| PE (1) | PE20020746A1 (enExample) |
| WO (1) | WO2001058869A2 (enExample) |
Families Citing this family (230)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE247097T1 (de) * | 1998-05-04 | 2003-08-15 | Univ Connecticut | Analgetische und immunomodulierende cannabinoiden |
| US7589220B2 (en) | 1998-06-09 | 2009-09-15 | University Of Connecticut | Inhibitors of the anandamide transporter |
| US7897598B2 (en) * | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
| US7161016B1 (en) | 1998-11-24 | 2007-01-09 | University Of Connecticut | Cannabimimetic lipid amides as useful medications |
| US7276613B1 (en) | 1998-11-24 | 2007-10-02 | University Of Connecticut | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| US7119108B1 (en) * | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US6900236B1 (en) * | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
| US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| DE60033834T2 (de) | 1999-10-18 | 2007-11-15 | The University Of Connecticut, Farmington | Für periphäre cannabinoid-rezeptoren selektive liganden |
| US7741365B2 (en) * | 1999-10-18 | 2010-06-22 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
| US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| US6943266B1 (en) * | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
| CA2435409A1 (en) | 2001-01-26 | 2002-08-01 | University Of Connecticut | Novel cannabimimetic ligands |
| CA2436133A1 (en) | 2001-01-29 | 2002-08-08 | University Of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
| EP1414775B1 (en) | 2001-07-13 | 2012-12-19 | The University of Connecticut | Bicyclic cannabinoid |
| WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| AU2002331766A1 (en) * | 2001-08-31 | 2003-03-18 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
| US7666867B2 (en) * | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
| US20040259936A1 (en) * | 2001-12-07 | 2004-12-23 | Nagarkatti Leonard C | Treatment of neoplasia |
| CA2478338A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
| CA2477604A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
| FR2838438A1 (fr) * | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
| WO2004103410A1 (en) * | 2002-06-06 | 2004-12-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods compositions and articles of manufacture for modulating bone growth |
| TW200402417A (en) * | 2002-06-21 | 2004-02-16 | Akzo Nobel Nv | 1-[(Indol-3-yl)carbonyl]piperazine derivatives |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| MXPA05000962A (es) | 2002-07-29 | 2005-05-16 | Hoffmann La Roche | Nuevos benzodioxoles. |
| WO2004017922A2 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
| HRP20050053A2 (en) | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| AU2003276919B2 (en) * | 2002-09-25 | 2013-05-16 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| AU2003267728A1 (en) * | 2002-10-18 | 2004-05-04 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| FR2847899B1 (fr) * | 2002-11-29 | 2006-04-28 | Sanofi Synthelabo | Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique |
| MXPA05005794A (es) | 2002-12-02 | 2005-08-16 | Hoffmann La Roche | Derivados de indazol como antagonistas del factor de liberacion de corticotropina. |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| US7135488B2 (en) | 2003-01-02 | 2006-11-14 | Hoffmann-La Roche Inc. | Pyrrolyl-thiazole derivatives |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| PL377848A1 (pl) | 2003-02-07 | 2006-02-20 | Daiichi Pharmaceutical Co., Ltd. | Pochodne pirazoli |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| SE0300705D0 (sv) * | 2003-03-14 | 2003-03-14 | Biolipox Ab | New compounds |
| TW200505902A (en) * | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| SE0300908D0 (sv) * | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| EP1622876A1 (en) * | 2003-05-07 | 2006-02-08 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| EP1633733B1 (en) * | 2003-05-20 | 2011-01-26 | The University of Tennessee Research Foundation | Cannabinoid derivatives, methods of making, and use thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| JP4786147B2 (ja) * | 2003-06-26 | 2011-10-05 | 武田薬品工業株式会社 | カンナビノイド受容体調節剤 |
| EP1498098B1 (en) | 2003-07-14 | 2006-05-03 | 3M Espe Ag | Adhesive composition with decreased polarity upon polymerization |
| WO2005012256A1 (en) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
| DE602004025354D1 (de) * | 2003-08-14 | 2010-03-18 | Hoffmann La Roche | Gabanerge modulatoren |
| MXPA06002853A (es) | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
| SA04250288B1 (ar) * | 2003-09-19 | 2008-07-19 | سولفاي فارماسوتيكالز بي . في | مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid |
| JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Ｍｓｄ株式会社 | 新規ピペリジン誘導体 |
| US7151097B2 (en) | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| CN100540005C (zh) * | 2003-12-17 | 2009-09-16 | 欧加农股份有限公司 | 作为大麻素cb1受体激动剂的三环的1-[(3-吲哚-3-基)羰基]哌嗪衍生物 |
| DE602004005893T2 (de) | 2003-12-17 | 2007-09-06 | N.V. Organon | Trizyklische 1-((3-indol-3-yl)-carbonyl)-piperazin-derivate als cannabinoid-cb1-rezeptoragonisten |
| ES2284081T3 (es) | 2003-12-19 | 2007-11-01 | Bristol-Myers Squibb Company | Heterociclos azabiciclicos como modulares de receptores canabinoides. |
| DE602004010299T2 (de) * | 2003-12-22 | 2008-09-18 | Memory Pharmaceuticals Corp. | Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen |
| TW200522944A (en) * | 2003-12-23 | 2005-07-16 | Lilly Co Eli | CB1 modulator compounds |
| GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
| ES2244314B1 (es) * | 2004-02-17 | 2007-02-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos. |
| GB0403864D0 (en) * | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
| BRPI0507786A (pt) * | 2004-02-20 | 2007-07-17 | Astrazeneca Ab | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos |
| TWI330635B (en) | 2004-03-05 | 2010-09-21 | Organon Nv | (indol-3-yl)-heterocycle derivatives |
| EA010887B1 (ru) * | 2004-03-24 | 2008-12-30 | Янссен Фармацевтика Н.В. | Тетрагидроиндазольные модуляторы каннабиноидов |
| RU2417225C2 (ru) * | 2004-03-25 | 2011-04-27 | Мемори Фармасьютиклз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7417063B2 (en) * | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| JP2007534692A (ja) | 2004-04-22 | 2007-11-29 | メモリー・ファーマシューティカルズ・コーポレイション | インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用 |
| JP2007538011A (ja) | 2004-05-07 | 2007-12-27 | メモリー・ファーマシューティカルズ・コーポレイション | １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用 |
| ES2324720T3 (es) * | 2004-05-10 | 2009-08-13 | F. Hoffmann-La Roche Ag | Pirrol o imidazol amidas para tratar la obesidad. |
| JP2008501758A (ja) | 2004-06-09 | 2008-01-24 | グラクソ グループ リミテッド | ピロロピリジン誘導体 |
| EP1787991B2 (en) * | 2004-07-28 | 2020-06-24 | Takeda Pharmaceutical Company Limited | PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE |
| AU2005271737A1 (en) | 2004-08-03 | 2006-02-16 | Wyeth | Indazoles useful in treating cardiovascular diseases |
| FR2874012B1 (fr) | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
| FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| WO2006032851A1 (en) | 2004-09-20 | 2006-03-30 | Biolipox Ab | Pyrazole compounds useful in the treatment of inflammation |
| US20080090836A1 (en) * | 2004-09-20 | 2008-04-17 | Peter Nilsson | Pyrazole Compounds Useful In The Treatment Of Inflammation |
| EP1797041A2 (en) * | 2004-09-27 | 2007-06-20 | Pfizer Products Inc. | Process for preparing bicyclic pyrazolyl compounds |
| JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ |
| ES2325773T5 (es) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
| SE0402763D0 (sv) * | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Nitro indazole derivatives |
| WO2006060461A1 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| JP4922946B2 (ja) * | 2004-12-21 | 2012-04-25 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての３−シクロアルキルカルボニルインドール類 |
| BRPI0517494A (pt) * | 2004-12-22 | 2008-10-14 | Memory Pharm Corp | composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi |
| JP2008525404A (ja) * | 2004-12-23 | 2008-07-17 | アストラゼネカ アクチボラグ | 治療剤 |
| WO2006076569A2 (en) * | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| CA2594477C (en) | 2005-01-21 | 2016-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US20080161251A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| WO2006084033A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US8937184B2 (en) | 2005-02-16 | 2015-01-20 | Abbvie B.V. | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators |
| BRPI0607439A2 (pt) * | 2005-02-16 | 2010-04-06 | Solvay Pharm Bv | compostos, composição farmacêutica, método de preparação de composições farmacêuticas, e, uso de um composto |
| TW200700387A (en) * | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
| WO2006101434A1 (en) * | 2005-03-22 | 2006-09-28 | Astrazeneca Ab | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| DE602006004197D1 (de) * | 2005-03-31 | 2009-01-22 | Janssen Pharmaceutica Nv | Querverweise von tetrahydrothiopyrano-pyrazol-cannabinoidmodulatoren zu verwandten anmeldungen |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| EP1902034B1 (en) * | 2005-06-02 | 2011-03-30 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| GB0514738D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Therapeutic agents |
| GB0516379D0 (en) * | 2005-08-09 | 2005-09-14 | Glaxo Group Ltd | Compounds |
| CA2618112A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
| BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
| AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
| EP1915131A4 (en) * | 2005-08-12 | 2012-07-25 | Astrazeneca Ab | PROCESS |
| US7763732B2 (en) | 2005-08-24 | 2010-07-27 | N.V. Organon | Indole derivatives |
| WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
| AU2006288153A1 (en) | 2005-09-07 | 2007-03-15 | Msd K.K. | Bicyclic aromatic substituted pyridone derivative |
| US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| CN101312724A (zh) * | 2005-09-23 | 2008-11-26 | 詹森药业有限公司 | 四氢-吲唑基大麻素调节剂 |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| GB2431105A (en) | 2005-10-12 | 2007-04-18 | Gw Pharma Ltd | Cannabinoids for the treatment of pulmonary disorders |
| TW200800911A (en) * | 2005-10-20 | 2008-01-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
| CA2627139A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
| EA200801108A1 (ru) * | 2005-10-31 | 2008-10-30 | Биолипокс Аб | Триазолы, пригодные для лечения воспалений |
| TW200732320A (en) * | 2005-10-31 | 2007-09-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
| EP1943225A1 (en) * | 2005-11-01 | 2008-07-16 | Biolipox AB | Pyrazoles useful in the treatment of inflammation |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| ES2381205T3 (es) | 2005-11-10 | 2012-05-24 | Msd K.K. | Derivado espiro aza-sustituido |
| WO2007079239A2 (en) * | 2005-12-30 | 2007-07-12 | Acadia Pharmaceuticals Inc. | Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof |
| PL2090570T3 (pl) | 2006-09-05 | 2012-03-30 | Kyowa Hakko Kirin Co Ltd | Pochodna imidazolu |
| JP5159630B2 (ja) | 2006-09-13 | 2013-03-06 | 協和発酵キリン株式会社 | 縮環複素環誘導体 |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| WO2008047544A1 (en) | 2006-09-28 | 2008-04-24 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| US20080242648A1 (en) * | 2006-11-10 | 2008-10-02 | Syndax Pharmaceuticals, Inc., A California Corporation | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| WO2008075013A1 (en) | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Modulators of cannabinoid receptor |
| WO2008085302A1 (en) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| TW200848039A (en) * | 2007-02-09 | 2008-12-16 | Astrazeneca Ab | Pharmaceutical compositions |
| TW200848417A (en) | 2007-02-22 | 2008-12-16 | Organon Nv | Indole derivatives |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| US7781650B2 (en) * | 2007-04-30 | 2010-08-24 | Monsanto Technology Llc | Plants and seeds of corn variety CV202909 |
| MX2009013293A (es) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009015180A2 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
| JPWO2009020137A1 (ja) * | 2007-08-06 | 2010-11-04 | 大日本住友製薬株式会社 | アミノピラゾールアミド誘導体 |
| SG183699A1 (en) * | 2007-08-10 | 2012-09-27 | Lundbeck & Co As H | Heteroaryl amide analogues |
| WO2009025785A2 (en) * | 2007-08-21 | 2009-02-26 | Merck & Co., Inc. | Cb2 receptor ligands for the treatment of pain |
| US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| WO2009067453A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| AR069700A1 (es) * | 2007-12-18 | 2010-02-10 | Sanofi Aventis | Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros. |
| BRPI0907122B8 (pt) | 2008-01-11 | 2021-05-25 | Albany Molecular Res Inc | compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos |
| WO2009105509A1 (en) * | 2008-02-21 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the cb2 receptor |
| WO2009106982A1 (en) * | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| WO2009106980A2 (en) * | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| JPWO2009110510A1 (ja) | 2008-03-06 | 2011-07-14 | Ｍｓｄ株式会社 | アルキルアミノピリジン誘導体 |
| NZ587799A (en) * | 2008-03-25 | 2012-06-29 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| US8815892B2 (en) | 2008-03-25 | 2014-08-26 | Affectis Pharmaceuticals Ag | P2X7R antagonists and their use |
| US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| CN102014897B (zh) | 2008-04-21 | 2015-08-05 | 西格纳姆生物科学公司 | 化合物、组合物和其制备方法 |
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JPWO2009154132A1 (ja) | 2008-06-19 | 2011-12-01 | Ｍｓｄ株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Ｍｓｄ株式会社 | ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体 |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| EP2350010B1 (en) | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| WO2011003012A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
| US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| US8637501B2 (en) | 2009-07-01 | 2014-01-28 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof |
| WO2011003007A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| WO2011044134A1 (en) | 2009-10-05 | 2011-04-14 | Albany Molecular Research, Inc. | Epiminocycloalkyl(b)indole derivatives as serotonin sub-type 6 (5-ht6) modulators and uses thereof |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
| WO2012088124A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof |
| KR20140027090A (ko) * | 2011-01-04 | 2014-03-06 | 노파르티스 아게 | 연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체 |
| AU2012207335A1 (en) | 2011-01-19 | 2013-07-25 | Albany Molecular Research, Inc. | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
| BR112013021126A2 (pt) * | 2011-02-18 | 2019-09-24 | Medivation Technologies Inc | método para reduzir a pressão sanguínea, método para aumentar o fluxo sanguíneo renal ou diminuir a reabsorção de sódio, método para tratar uma doença, kit, composto e composição farmacêutica |
| MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
| US9340500B2 (en) | 2011-04-20 | 2016-05-17 | Shionogi & Co., Ltd. | Aromatic heterocyclic derivative having TRPV4-inhibiting activity |
| JP2014517074A (ja) | 2011-06-24 | 2014-07-17 | アムジエン・インコーポレーテツド | Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用 |
| MY157429A (en) | 2011-06-24 | 2016-06-15 | Amgen Inc | Trpm8 antagonists and their use in treatments |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| CA2875842A1 (en) * | 2012-05-11 | 2013-11-14 | The University Of Utah Research Foundation | Compounds with trpv4 activity, compositions and associated methods thereof |
| WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| RU2520967C1 (ru) * | 2013-02-08 | 2014-06-27 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | СИММЕТРИЧНЫЕ ДИИМИНЫ НА ОСНОВЕ КАМФОРЫ - ИНГИБИТОРЫ РЕПРОДУКЦИИ ВИРУСА ГРИППА (ШТАММ A/California/07/09 (H1N1)pdm09) |
| WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| UA118666C2 (uk) * | 2013-03-07 | 2019-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні піразолу |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| KR20160002857A (ko) | 2013-05-02 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | CB2 수용체 작용제로서의 피롤로[2,3-d]피리미딘 유도체 |
| HUE039589T2 (hu) | 2013-05-02 | 2019-01-28 | Hoffmann La Roche | Purinszármazékok mint CB2 receptor agonisták |
| EA201592263A1 (ru) | 2013-06-05 | 2016-05-31 | Синерджи Фармасьютикалз, Инк. | Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования |
| EP3943497A1 (en) | 2013-09-06 | 2022-01-26 | F. Hoffmann-La Roche AG | Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US20170157135A1 (en) * | 2013-11-25 | 2017-06-08 | Novogen Limited | Functionalised and substituted indoles as anti-cancer agents |
| EP3186242B1 (en) | 2014-08-29 | 2021-10-06 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| WO2017040963A1 (en) | 2015-09-03 | 2017-03-09 | Forma Therapeutics, Inc. | [6,6] fused bicyclic hdac8 inhibitors |
| EA033826B1 (ru) | 2015-09-10 | 2019-11-29 | Suven Life Sciences Ltd | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 |
| CA3010615C (en) | 2016-01-14 | 2024-02-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| PL3419979T3 (pl) | 2016-02-23 | 2020-06-29 | Pfizer Inc. | Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe |
| AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| TW201831478A (zh) | 2016-12-02 | 2018-09-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環醯胺化合物及其使用方法 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| CN108794379A (zh) * | 2017-04-26 | 2018-11-13 | 华东师范大学 | 1h-吲哚-2-甲酰胺衍生物及其制备方法和应用 |
| MA49560B1 (fr) | 2017-07-14 | 2024-05-31 | Hoffmann La Roche | Composés cétoniques bicycliques et leurs procédés d'utilisation |
| SG11202002877RA (en) | 2017-10-31 | 2020-04-29 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof |
| US12421225B2 (en) | 2018-09-10 | 2025-09-23 | Kaken Pharmaceutical Co., Ltd. | Heteroaromatic amide derivative and medicament containing the same |
| CN109020860B (zh) * | 2018-09-25 | 2021-06-22 | 宝鸡文理学院 | 一种2-芳基-3-酯基多取代吡咯类化合物及其合成精制方法 |
| AR117122A1 (es) | 2018-11-20 | 2021-07-14 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
| CN113302193A (zh) | 2019-01-11 | 2021-08-24 | 豪夫迈·罗氏有限公司 | 双环吡咯并三唑酮化合物及其使用方法 |
| TW202045476A (zh) | 2019-02-13 | 2020-12-16 | 美商默沙東藥廠 | 5-烷基吡咯啶食慾素受體促效劑 |
| EP3923933A4 (en) | 2019-02-13 | 2022-08-17 | Merck Sharp & Dohme Corp. | PYRROLIDINOREXINE RECEPTOR AGONISTS |
| WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| TR202002933A2 (tr) * | 2020-02-26 | 2021-09-21 | Bahcesehir Ueniversitesi | Nörodejenerati̇f hastaliklarin tedavi̇si̇nde kullanilmak üzere yeni̇ mao-b i̇nhi̇bi̇törü drg-maob-1 |
| US20230067205A1 (en) * | 2020-07-29 | 2023-03-02 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
| MX2023001840A (es) | 2020-08-18 | 2023-03-13 | Merck Sharp & Dohme Llc | Agonistas de bicicloheptano pirrolidina de los receptores de orexina. |
| WO2024052684A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Antibody drug conjugate comprising nmt inhibitor and its use |
| WO2026020111A1 (en) * | 2024-07-18 | 2026-01-22 | Washington University | Compositions of novel cannabinoid receptor modulators and methods of use thereof |
| CN119330867B (zh) * | 2024-09-03 | 2025-12-02 | 常州大学 | 一种吡咯酰胺类衍生物及其制备方法和作为β2-肾上腺素受体别构拮抗剂的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5632549A (en) | 1979-08-27 | 1981-04-02 | Toyo Ink Mfg Co Ltd | Pigment composition |
| US4581354A (en) | 1984-08-06 | 1986-04-08 | Sterling Drug Inc. | 3-arylcarbonyl- and 3-cycloalkylcarbonyl-1-aminoalkyl-1H-indoles, compositions and use |
| US5013732A (en) | 1984-08-06 | 1991-05-07 | Sterling Drug Inc. | 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles |
| US4748247A (en) * | 1986-10-21 | 1988-05-31 | American Home Products Corporation | 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists |
| NZ226032A (en) * | 1987-09-03 | 1991-12-23 | Glaxo Group Ltd | 2-(imidazolylmethyl)-pyrido or-azepino(4,3-b)indole-1(2h)-one derivatives; preparatory processes and pharmaceutical compositions |
| JP2602915B2 (ja) * | 1987-09-03 | 1997-04-23 | グラクソ、グループ、リミテッド | ラクタム誘導体 |
| AU631131B2 (en) * | 1988-08-02 | 1992-11-19 | Glaxo Group Limited | Lactam derivatives |
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| IE903957A1 (en) * | 1989-11-06 | 1991-05-08 | Sanofi Sa | Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present |
| PT95899A (pt) | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
| JPH03161470A (ja) * | 1989-11-17 | 1991-07-11 | Nisshin Flour Milling Co Ltd | インドール誘導体 |
| IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| CA2036307C (en) * | 1990-03-08 | 2002-07-09 | Susan Jean Ward | 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method |
| US5102889B1 (en) * | 1990-09-27 | 1993-05-11 | 2-(4-piperidinyl)-1h-pyrido(4,3-b)indol-1-ones and related compounds | |
| US5189041A (en) * | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
| US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| PT633886E (pt) | 1992-04-03 | 2001-03-30 | Upjohn Co | Aminas biciclicas-heterociclicas farmaceuticamente activas |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| WO1994020126A1 (en) * | 1993-03-03 | 1994-09-15 | Fujisawa Pharmaceutical Co., Ltd. | Use of peptides for the manufacture of a medicament |
| EP0648208A1 (en) * | 1993-04-05 | 1995-04-19 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives as testosterone 5 alpha-reductase inhibitors |
| US5681954A (en) | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
| WO1995000536A1 (en) * | 1993-06-22 | 1995-01-05 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds |
| EP0746544B1 (en) * | 1994-02-22 | 1998-09-09 | Merrell Pharmaceuticals Inc. | Novel indole derivatives useful to treat estrogen-related neoplasms and disorders |
| EP0774460A1 (en) * | 1994-03-30 | 1997-05-21 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compound and use thereof as medicine |
| GB9420521D0 (en) * | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
| EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
| US5532237A (en) * | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| US5567711A (en) | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
| FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| AU717422B2 (en) | 1995-09-01 | 2000-03-23 | Eli Lilly And Company | Indolyl neuropeptide Y receptor antagonists |
| AU1618697A (en) | 1996-02-06 | 1997-08-28 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| FR2745003B1 (fr) * | 1996-02-16 | 1998-04-03 | Adir | Nouveaux pseudopeptides derives de neurokinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6100259A (en) | 1997-01-21 | 2000-08-08 | Smithkline Beecham Corporation | Cannabinoid receptor modulators |
| US5948777A (en) * | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
| HUP0004400A3 (en) * | 1997-11-05 | 2002-10-28 | Novartis Ag | Dipeptide nitriles, process for their preparation, pharmaceutical compositions comprising thereof and their use |
| PL192083B1 (pl) * | 1997-11-18 | 2006-08-31 | Dupont Pharmaceuticals Res Lab | Pochodne amin cyklicznych i ich zastosowanie |
| JP2002515891A (ja) * | 1997-12-19 | 2002-05-28 | スミスクライン・ビーチャム・コーポレイション | 新規なピペリジン含有化合物 |
| AU772477B2 (en) | 1998-08-28 | 2004-04-29 | Scios Inc. | Inhibitors of p38-alpha kinase |
-
2001
- 2001-02-08 AU AU2001234958A patent/AU2001234958A1/en not_active Abandoned
- 2001-02-08 JP JP2001558420A patent/JP2004502642A/ja active Pending
- 2001-02-08 CA CA002399791A patent/CA2399791A1/en not_active Abandoned
- 2001-02-08 WO PCT/US2001/004131 patent/WO2001058869A2/en not_active Ceased
- 2001-02-08 EP EP01907144A patent/EP1254115A2/en not_active Withdrawn
- 2001-02-08 US US09/779,109 patent/US6653304B2/en not_active Expired - Lifetime
- 2001-02-09 AR ARP010100611A patent/AR027406A1/es unknown
- 2001-02-09 PE PE2001000145A patent/PE20020746A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101611013B (zh) | 作为5-ht2a血清素受体调节剂用于治疗与其相关病症的吡唑衍生物 | |
| AU2007254244B2 (en) | 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | |
| EP2018371B1 (en) | Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| US6653304B2 (en) | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases | |
| HRP20170338T1 (hr) | Fluorometil-supstituirani pirolkarboksamidi | |
| ES2314750T3 (es) | Derivados de 3-fenil-pirazol como moduladores del receptor 5ht-2a de la serotonina utiles para el tratamiento de trastornos relacionados con el mismo. | |
| FI104069B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 3-(fenyyli- tai sykloalkyyli)-3-hydroksi-1-fenyylisulfonyyli-2-indoliinikarboksamidijohdannaisten valmistamiseksi | |
| US8293770B2 (en) | Pyrrolidine derivatives as NK-3 receptor antagonists | |
| JP2013516415A5 (enExample) | ||
| ES2324710T3 (es) | Indolinonas sustituidas con heterociclos y su uso como inhibidores de receptores de tirosina quinasa. | |
| JP2010516635A5 (enExample) | ||
| JP2009541461A5 (enExample) | ||
| JP2014521595A5 (enExample) | ||
| AU2013249714A1 (en) | Indolin-2-one derivatives as protein kinase inhibitors | |
| JP2012502975A5 (enExample) | ||
| JP2005535655A (ja) | ムスカリン性受容体拮抗剤としてのアザビシクロ誘導体 | |
| WO2014133056A1 (ja) | ２－アシルアミノチアゾール誘導体またはその塩 | |
| JP2009525312A (ja) | スルホンアミド誘導体、これの調製および治療への応用 | |
| JP2006525299A5 (enExample) | ||
| CA2329881A1 (en) | Compounds with growth hormone releasing properties | |
| CN118574807A (zh) | 抑制单酰基甘油脂肪酶（magl） | |
| KR101304802B1 (ko) | 3-(벤질아미노)-피롤리딘 유도체 및 이의 ｎｋ-3 수용체 길항제로서의 용도 | |
| US5565579A (en) | (1H-indol-1-yl)-2-(amino)acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides | |
| JP2015506967A (ja) | イミダゾリルケトン誘導体ａｓｄアルドステロン合成酵素阻害剤 | |
| JP5243274B2 (ja) | ４型メラノコルチン受容体アゴニストのピペリジノイルピロリジン |